The Cabinet Committee on Economic Affairs (CCEA) has approved pharmaceutical major Lupin’s proposal to raise the foreign institutional investment limit to 49% from 33%. With this, the company is expected to attract Rs 6,099 crore.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1842.50 |
| Dr. Reddys Lab | 1310.35 |
| Cipla | 1373.30 |
| Zydus Lifesciences | 941.40 |
| Lupin | 2465.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: